KLI

Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma

Metadata Downloads
Publisher
EUROPEAN JOURNAL OF CANCER
Language
영어
ISSN
0959-8049
Citation Volume
163
Citation Number
0
Citation Start Page
55
Citation End Page
65
Appears in Collections:
Medicine > Nursing
Authorize & License
  • Authorize공개
Files in This Item:
  • There are no files associated with this item.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.